We need to find new treatments for acute myeloid leukaemia, particularly for children whose disease comes back. Dr Srdan Rogosic is developing a new type of CAR-T cell therapy which he hopes will increase the chances of survival for these children.

Project Details

  • Project Title

    Safety enhanced CAR T cell therapy in paediatric acute myeloid leukaemia

  • Lead Researcher

    Dr Srdan Rogosic

  • Research Centre

    UCL Great Ormond Street Institute of Child Health

  • City & Institution Postcode

    London WC1N 1EH

  • Start Date

    10 February 2020

  • Duration

    36 months

  • Grant Amount


Researcher in lab with microscope looking at camera Srdan Rogosic


Acute myeloid leukaemia (AML) is a rare condition caused by the body overproducing myeloid cells, a type of white blood cell. It is the second most common childhood leukaemia, with around 60 children diagnosed every year in the UK. If AML comes back after initial therapy, it can become aggressive and very difficult to cure. We desperately need to find new treatments for childhood AML which will improve the chances of survival for children with this cancer. CAR-T cell therapy is an exciting new type of cancer treatment. It works by instructing T cells from the body’s immune system to attack cancer cells which display a particular molecule on their surface. For example, a CAR­‑T cell therapy called Kymriah was approved in 2018 by NHS England to treat another type of leukaemia in children and young people. It targets a molecule called CD19, which the leukaemia cells produce lots of. However, right now there isn’t an equivalent CAR‑T cell therapy for AML. One of the reasons for this is that AML cells do not all look alike. This means that a CAR‑T cell therapy which targets only one molecule might not kill all the AML cells. In addition, the stem cells in bone marrow which produce our blood can look similar to AML cells. This means that a CAR‑T cell therapy for AML might attack these stem cells, which could cause devastating side effects. Dr Srdan Rogosic hopes to overcome these obstacles and develop a new CAR‑T cell therapy for AML. His plan is to develop a therapy which could target as many as three separate molecules, instead of just one. He hopes that this would mean the treatment will kill more AML cells, and stop the AML from coming back. Dr Rogosic will test his new treatment on AML cells grown in the lab, on samples donated by patients, and on AML cells in preclinical models. During this project, he will also test a new way to protect our body’s normal blood stem cells. This could mean that the CAR‑T cell therapy will not attack these cells, and so reduce the chances of severe side-effects.

What difference will this project make?

We need new treatments for children with AML whose cancer comes back. In this project, Dr Rogosic will develop a new treatment for AML which could give these children a better chance of survival from this aggressive form of cancer. Treatments  

About the Research Team

Dr Srdan Rogosic graduated with a medical degree from the University of Zagreb School of Medicine in Croatia, in 2011. After graduating, Dr Rogosic started his Paediatrics training at Leeds Children’s Hospital, before continuing his Haematology specialty training in London. He continues being at the frontline by undertaking his clinical role as a Haematology Specialist Registrar at Great Ormond Street Hospital. He is particularly interested in developing new treatments for children and young people. Dr Srdan is working with Dr Sara Ghorashian and Dr Martin Pule, who both have significant expertise in the development and delivery of CAR T cell therapy. Dr Ghorashian is a consultant paediatric haematologist at Great Ormond Street Hospital. She has translated a novel CAR T cell programme into clinical practice in under two years. Dr Martin Pule is the director of the UCL CAR programme and has a track record for being at the forefront of innovation in CAR engineering.
Newsletter icon
Newsletter icon

Sign up to our e-newsletter today

Sign up to our e-newsletter and receive exclusive stories straight to your inbox. You will also find out about our latest childhood cancer research news along with updates on our fundraising events, charity news and opportunities to support us. Don’t miss out!

By signing up to this newsletter I agree to receive general and financial appeal emails from Children with Cancer UK